Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients.

With Nobel prize-winning science leadership and renowned researchers, our work is founded on science from the University of Sydney, Australia. Biosceptre is headquartered in the UK and has research underway in both Sydney and Cambridge, UK.

Our pioneering team discovered the oncology target nfP2X7 – which is shown to be present on the cell surface of a wide range of tumour types, including lung, breast, colorectal and prostate. As the leaders in this area, we currently have several nfP2X7-focused programs approaching clinical stage that, if successful, have the potential to deliver real improvements to outcomes for millions of cancer patients worldwide.

Supported by the ongoing collaboration with global experts and major research institutes, Biosceptre continues to drive innovation and pioneer the future of nfP2X7-targeted oncology therapeutics.